« Back to News

Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics

December 11, 2019

Vancouver, British Columbia – (December 11th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to be featured in the official magazine of the Canadian Trade Commissioner Service (TCS) Life Sciences Special Edition. Please find below the link for the article on BioMark.

 

https://www.tradecommissioner.gc.ca/canadexport/0004195.aspx?lang=eng

 

The complete special edition report is available at https://www.tradecommissioner.gc.ca/canadexport/index.aspx?lang=eng

 

 

BioMark is very grateful of TCS and its CanExport Innovation (CXI) program. “The CXI program has been instrumental in funding and supporting our international market exploration to the United States, Japan and China. These are all important oncology related markets that we are targeting to introduce our cancer diagnostics solution”, says BioMark CEO and President Rashid Ahmed.”

 

 

About The CXI Program

 

The CXI program, formerly called Going Global Innovation, offers funding to support innovators from Canadian small and medium enterprises (SMEs), academic institutions and non-government research centres looking for foreign partners for the purpose of establishing collaborative research & development agreements. It helps companies offset a variety of costs to help innovators co-develop, validate or adapt their technologies, with the aim to commercialize.

Press Release – Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics